Short answer
MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). MBX Biosciences announced an obesity portfolio update, including initial Phase 1 data for MBX 4291.
MBX Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- MBX Biosciences announced an obesity portfolio update, including initial Phase 1 data for MBX 4291
- MBX 4291 data support potential once-monthly dosing, a possible convenience and differentiation advantage
- Obesity Day presentation provides additional portfolio details and clinical context for investors
- Press release and presentation furnished as Exhibits 99.1 and 99.2 for review
Item 8.01 · Other Events
- MBX 4291 showed 7% mean weight loss at eight weeks, though blinded data included two placebo subjects
- Pharmacokinetics support once-monthly dosing, with approximately 26-day half-life and 13–14-day Tmax
- 180 mg single dose reached maximum tolerated dose, with predominantly mild dose-dependent gastrointestinal events
- MBX 5765 nominated as lead amycretin prodrug; IND-enabling studies expected in Q2 2026
- Imapextide achieved PBH proof of concept, but MBX will not fund a Phase 2b trial, reallocating resources to canvuparatide and obesity programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MBX Biosciences, Inc. 8-K filings
Get the next MBX 8-K as it lands
Follow MBX for push alerts, or ask the research agent what this filing means.